These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21454344)

  • 1. Antibiotic use and the risk of carbapenem-resistant extended-spectrum-{beta}-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study.
    Kritsotakis EI; Tsioutis C; Roumbelaki M; Christidou A; Gikas A
    J Antimicrob Chemother; 2011 Jun; 66(6):1383-91. PubMed ID: 21454344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study.
    Mosqueda-Gómez JL; Montaño-Loza A; Rolón AL; Cervantes C; Bobadilla-del-Valle JM; Silva-Sánchez J; Garza-Ramos U; Villasís-Keever A; Galindo-Fraga A; Palacios GM; Ponce-de-León A; Sifuentes-Osornio J
    Int J Infect Dis; 2008 Nov; 12(6):653-9. PubMed ID: 18511321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel.
    Samra Z; Ofir O; Lishtzinsky Y; Madar-Shapiro L; Bishara J
    Int J Antimicrob Agents; 2007 Dec; 30(6):525-9. PubMed ID: 17931835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spread of Klebsiella pneumoniae isolates producing OXA-48 β-lactamase in a Tunisian university hospital.
    Ktari S; Mnif B; Louati F; Rekik S; Mezghani S; Mahjoubi F; Hammami A
    J Antimicrob Chemother; 2011 Jul; 66(7):1644-6. PubMed ID: 21565807
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: A VIM-1-metallo-beta-lactamase-producing Klebsiella pneumoniae clinical isolate in an acute hospital in Germany.
    Shah PM
    Int J Antimicrob Agents; 2009 Oct; 34(4):381. PubMed ID: 19502012
    [No Abstract]   [Full Text] [Related]  

  • 6. Extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.
    Shanthi M; Sekar U
    J Assoc Physicians India; 2010 Dec; 58 Suppl():41-4. PubMed ID: 21568008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of an outbreak of antibiotic-resistant Klebsiella pneumoniae at a tertiary care medical center.
    Filozov A; Visintainer P; Carbonaro C; Aguero-Rosenfeld M; Wormser GP; Montecalvo MA
    Am J Infect Control; 2009 Nov; 37(9):723-8. PubMed ID: 19501935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of carbapenem resistance due to porin loss in an extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae strain during meropenem therapy.
    Webster DP; Gaulton T; Woodford N; Pike R; Turton J; Perry C; Bowler IC
    Int J Antimicrob Agents; 2010 Dec; 36(6):575-6. PubMed ID: 20869852
    [No Abstract]   [Full Text] [Related]  

  • 10. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.
    Lautenbach E; Patel JB; Bilker WB; Edelstein PH; Fishman NO
    Clin Infect Dis; 2001 Apr; 32(8):1162-71. PubMed ID: 11283805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-class resistance to non-beta-lactam antimicrobials in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.
    Procop GW; Tuohy MJ; Wilson DA; Williams D; Hadziyannis E; Hall GS
    Am J Clin Pathol; 2003 Aug; 120(2):265-7. PubMed ID: 12931557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase.
    Elliott E; Brink AJ; van Greune J; Els Z; Woodford N; Turton J; Warner M; Livermore DM
    Clin Infect Dis; 2006 Jun; 42(11):e95-8. PubMed ID: 16652304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.
    Lee CH; Su LH; Tang YF; Liu JW
    J Antimicrob Chemother; 2006 Nov; 58(5):1074-7. PubMed ID: 16971415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endoscopy-associated transmission of carbapenem-resistant Klebsiella pneumoniae producing KPC-2 beta-lactamase.
    Naas T; Cuzon G; Babics A; Fortineau N; Boytchev I; Gayral F; Nordmann P
    J Antimicrob Chemother; 2010 Jun; 65(6):1305-6. PubMed ID: 20382724
    [No Abstract]   [Full Text] [Related]  

  • 15. An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase.
    Peña C; Pujol M; Ardanuy C; Ricart A; Pallarés R; Liñares J; Ariza J; Gudiol F
    J Hosp Infect; 2001 Jan; 47(1):53-9. PubMed ID: 11161899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)].
    Angel Díaz M; Ramón Hernández J; Martínez-Martínez L; Rodríguez-Baño J; Pascual A;
    Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):503-10. PubMed ID: 19329230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, antibiotic susceptibility pattern and production of extended-spectrum beta-lactamases amongst clinical isolates of Klebsiella pneumoniae at Armed Forces Hospital in Saudi Arabia.
    Ahmad S; Al-Juaid NF; Alenzi FQ; Mattar EH; Bakheet Oel-S
    J Coll Physicians Surg Pak; 2009 Apr; 19(4):264-5. PubMed ID: 19356348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes.
    Souli M; Galani I; Antoniadou A; Papadomichelakis E; Poulakou G; Panagea T; Vourli S; Zerva L; Armaganidis A; Kanellakopoulou K; Giamarellou H
    Clin Infect Dis; 2010 Feb; 50(3):364-73. PubMed ID: 20041768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of control group selection in the analysis of risk factors for extended spectrum beta-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study.
    Behar PR; Teixeira PJ; Fachel JM; Kalil AC
    J Hosp Infect; 2008 Feb; 68(2):123-9. PubMed ID: 18192077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.